FY2026 Earnings Estimate for Azitra Issued By Zacks Research

Azitra, Inc. (NYSEAMERICAN:AZTR) – Analysts at Zacks Research lifted their FY2026 earnings per share (EPS) estimates for shares of Azitra in a research report issued to clients and investors on Wednesday, March 4th. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings of ($0.71) per share for the year, up from their prior forecast of ($0.88). The consensus estimate for Azitra’s current full-year earnings is ($2.78) per share. Zacks Research also issued estimates for Azitra’s FY2027 earnings at ($0.55) EPS.

Azitra Trading Up 2.5%

Shares of NYSEAMERICAN:AZTR opened at $0.18 on Friday. The stock has a fifty day simple moving average of $0.24 and a two-hundred day simple moving average of $0.47. Azitra has a 12-month low of $0.15 and a 12-month high of $2.66.

Azitra Company Profile

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.